Stock EVGN EVOGENE LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Evogene Ltd. Share Price Nasdaq

Equities

EVGN

IL0011050551

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:01 31/05/2024 BST 		5-day change 1st Jan Change
0.745 USD -2.75% Intraday chart for Evogene Ltd. -9.14% -11.31%
05-23 Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M MT
05-23 Evogene Ltd. Provides Revenue Guidance for the Year 2024 CI

Financials

Sales 2024 * 17M 1.33B Sales 2025 * 31.5M 2.47B Capitalization 37.74M 2.96B
Net income 2024 * -20M -1.57B Net income 2025 * -17M -1.33B EV / Sales 2024 * 2.22 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.2 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 142
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.34%
More Fundamentals * Assessed data

Chart Evogene Ltd.

Dynamic Chart

Latest news about Evogene Ltd.

Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M MT
Evogene Ltd. Provides Revenue Guidance for the Year 2024 CI
Transcript : Evogene Ltd., Q1 2024 Earnings Call, May 23, 2024
Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd CI
Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq MT
Transcript : Evogene Ltd., Q4 2023 Earnings Call, Mar 07, 2024
Evogene Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Evogene Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Evogene Unit, Corteva Agriscience Identify New Potential Class of Herbicidal Molecules MT
AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides CI
Casterra Announces New Agreements with Subsidiary of Evogen Ltd., to Meet Growing Demand for Its Elite Castor Seed Varieties CI
Evogene Files $200 Million Mixed Shelf MT
Evogene Ltd. and Verb Biotics LLC Enters into Collaboration Agreement CI
Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024 CI
More news

Latest transcript on Evogene Ltd.

Logo Evogene Ltd.
Evogene Ltd., Q1 2024 Earnings Call, May 23, 2024
More transcripts

Analyst Recommendations on Evogene Ltd.

Alliance Global Starts Evogene at Buy With $1.85 Price Target MT
Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating MT
EVOGENE : Aegis Capital Starts Evogene at Buy MT
EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target MT
More recommendations

Press releases Evogene Ltd.

Evogene : Corporate Presentation PU
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma - Evogene AQ
Evogene : Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma PU
Evogene Reports First Quarter 2024 Financial Results - Evogene AQ
Evogene : Q1 2024 Consolidated Financial Statements PU
More press releases

Quotes and Performance

1 day-2.75%
1 week-9.14%
1 month+6.58%
3 months-18.24%
6 months+14.58%
Current year-11.31%
More quotes

Highs and lows

1 week
0.73
Extreme 0.7315
0.79
1 month
0.64
Extreme 0.6382
0.90
Current year
0.61
Extreme 0.612
1.04
1 year
0.45
Extreme 0.4502
1.44
3 years
0.45
Extreme 0.4502
4.10
5 years
0.45
Extreme 0.4502
10.24
10 years
0.45
Extreme 0.4502
16.96
More quotes

Managers and Directors - Evogene Ltd.

Managers TitleAgeSince
Ofer Haviv CEO
 Chief Executive Officer 58 31/12/01
Yaron Eldad DFI
 Director of Finance/CFO 57 31/03/22
Mark Kapel CTO
 Chief Tech/Sci/R&D Officer 48 31/12/04
Members of the board TitleAgeSince
Dan Falk BRD
 Director/Board Member 79 16/11/21
Sarit Firon CHM
 Chairman 58 10/08/16
Leon Recanati BRD
 Director/Board Member 76 30/04/05
More insiders

Quotes

Date Price Change Volume
31/05/24 0.745 -2.75% 34,748
30/05/24 0.7661 -0.48% 37,300
29/05/24 0.7698 -0.16% 50,174
28/05/24 0.771 -5.96% 104,018
24/05/24 0.8199 +13.86% 71,213

Delayed Quote Nasdaq, May 31, 2024 at 09:30 pm

More quotes

Company Profile

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Sector
Biotechnology & Medical Research
Calendar
03/06/2024 - American Society of Clinical Oncology Meeting - Abstract No: 8631
More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EVGN Stock
  4. EVGN Stock